Literature DB >> 16390366

Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression.

M P Freeman1, J R Hibbeln, K L Wisner, B H Brumbach, M Watchman, A J Gelenberg.   

Abstract

OBJECTIVE: Postpartum depression (PPD) affects 10-15% of mothers. Omega-3 fatty acids are an intriguing potential treatment for PPD.
METHOD: The efficacy of omega-3 fatty acids for PPD was assessed in an 8-week dose-ranging trial. Subjects were randomized to 0.5 g/day (n = 6), 1.4 g/day (n = 3), or 2.8 g/day (n = 7).
RESULTS: Across groups, pretreatment Edinburgh Postnatal Depression Scale (EPDS) and Hamilton Rating Scale for Depression (HRSD) mean scores were 18.1 and 19.1 respectively; post-treatment mean scores were 9.3 and 10.0. Percent decreases on the EPDS and HRSD were 51.5% and 48.8%, respectively; changes from baseline were significant within each group and when combining groups. Groups did not significantly differ in pre- or post-test scores, or change in scores. The treatment was well tolerated.
CONCLUSION: This study was limited by small sample size and lack of placebo group. However, these results support further study of omega-3 fatty acids as a treatment for PPD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16390366     DOI: 10.1111/j.1600-0447.2005.00660.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  41 in total

Review 1.  Maternal omega-3 fatty acid supplementation and risk for perinatal maternal depression.

Authors:  Janet M Wojcicki; Melvin B Heyman
Journal:  J Matern Fetal Neonatal Med       Date:  2010-10-07

Review 2.  Role of docosahexaenoic acid in maternal and child mental health.

Authors:  Usha Ramakrishnan; Beth Imhoff-Kunsch; Ann M DiGirolamo
Journal:  Am J Clin Nutr       Date:  2009-01-28       Impact factor: 7.045

3.  Long chain omega-3 fatty acids intake, fish consumption and mental disorders in the SUN cohort study.

Authors:  Almudena Sanchez-Villegas; Patricia Henríquez; Adolfo Figueiras; Felipe Ortuño; Francisca Lahortiga; Miguel A Martínez-González
Journal:  Eur J Nutr       Date:  2007-08-23       Impact factor: 5.614

Review 4.  Pharmacotherapy of postpartum depression: an update.

Authors:  Deborah R Kim; C Neill Epperson; Amy R Weiss; Katherine L Wisner
Journal:  Expert Opin Pharmacother       Date:  2014-04-29       Impact factor: 3.889

Review 5.  Complementary and alternative medicine therapies for perinatal depression.

Authors:  Kristina M Deligiannidis; Marlene P Freeman
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2013-08-26       Impact factor: 5.237

6.  The Mothers, Omega-3, and Mental Health Study: a double-blind, randomized controlled trial.

Authors:  Ellen L Mozurkewich; Chelsea M Clinton; Julie L Chilimigras; Susan E Hamilton; Lucy J Allbaugh; Deborah R Berman; Sheila M Marcus; Vivian C Romero; Marjorie C Treadwell; Kristie L Keeton; Anjel M Vahratian; Ronald M Schrader; Jianwei Ren; Zora Djuric
Journal:  Am J Obstet Gynecol       Date:  2013-04       Impact factor: 8.661

7.  Omega-3 fatty acids and supportive psychotherapy for perinatal depression: a randomized placebo-controlled study.

Authors:  Marlene P Freeman; Melinda Davis; Priti Sinha; Katherine L Wisner; Joseph R Hibbeln; Alan J Gelenberg
Journal:  J Affect Disord       Date:  2008-02-21       Impact factor: 4.839

8.  Dopamine receptor alterations in female rats with diet-induced decreased brain docosahexaenoic acid (DHA): interactions with reproductive status.

Authors:  Paul F Davis; Marlies K Ozias; Susan E Carlson; Gregory A Reed; Michelle K Winter; Kenneth E McCarson; Beth Levant
Journal:  Nutr Neurosci       Date:  2010-08       Impact factor: 4.994

9.  N-3 (omega-3) Fatty acids in postpartum depression: implications for prevention and treatment.

Authors:  Beth Levant
Journal:  Depress Res Treat       Date:  2010-10-27

10.  Update and critique of natural remedies as antidepressant treatments.

Authors:  David Mischoulon
Journal:  Obstet Gynecol Clin North Am       Date:  2009-12       Impact factor: 2.844

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.